Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Okyo Pharma Limited (OKYO.LN)

Okyo Pharma Limited (OKYO.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
Help
Go To:
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 34,835
  • Shares Outstanding, K 1,415,040
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,825 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.01
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.400 unch
on 05/19/23
2.715 -48.43%
on 05/09/23
-0.150 (-9.68%)
since 04/19/23
3-Month
1.350 +3.70%
on 04/12/23
6.000 -76.67%
on 02/20/23
-4.000 (-74.07%)
since 02/17/23
52-Week
1.350 +3.70%
on 04/12/23
8.500 -83.53%
on 02/17/23
-3.100 (-68.89%)
since 05/19/22
Free Barchart Webinars! Live educational sessions using site features to explore today's markets.

Most Recent Stories

More News
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments FinancialNewsMedia - Tue May 2, 2023

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END

OKYO : 1.0476 (-2.09%)
OKYO.LN : 1.400 (-24.32%)
NVS : 104.37 (+0.50%)
ALDX : 4.84 (+0.62%)
OCUL : 8.80 (+3.29%)
EYPT : 9.09 (+8.86%)
Wall Street - NYSE Stock Market American Flag
Stocks Climb Before the Open as Investors Weigh Economic Outlook, U.S. JOLTs Report in Focus Barchart - Tue Apr 4, 2023

June S&P 500 futures (ESM23) are up +0.29%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.61% this morning after three major U.S. benchmark indices finished the regular session mixed as weaker-than-expected...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
TSLA : 352.02 (+3.65%)
VORB : 0.0769 (-34.83%)
OKYO.LN : 1.400 (-24.32%)
BFLY : 3.26 (-0.91%)
AMC : 4.51 (+0.45%)
ONCT : 1.1296 (-2.62%)
EVO : 4.43 (-17.20%)
HLN : 9.64 (+0.94%)
CRBG : 31.90 (+1.37%)
OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm Business Wire - Tue Aug 30, 2022

OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, plans a Q4 2022...

OKYO : 1.0476 (-2.09%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited - PDMR Dealing Globe Newswire - Thu Jun 9, 2022

LONDON and NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing...

OKYO : 1.0476 (-2.09%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited - PDMR Dealing Globe Newswire - Fri May 20, 2022

LONDON and BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a life sciences company focused on the discovery and...

OKYO : 1.0476 (-2.09%)
EMMLF : 0.0137 (-32.51%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited Announces Closing of Public Offering and Nasdaq Listing Globe Newswire - Thu May 19, 2022

LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a life sciences company focused...

OKYO : 1.0476 (-2.09%)
EMMLF : 0.0137 (-32.51%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited - PDMR Dealing Globe Newswire - Wed May 18, 2022

LONDON and NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a biotechnology company focused on the discovery and...

OKYO : 1.0476 (-2.09%)
EMMLF : 0.0137 (-32.51%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited Announces Pricing of Initial Public Offering of ADSs in the U.S. with director participation Globe Newswire - Tue May 17, 2022

LONDON, May 17, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), a life sciences company focused on the...

OKYO.LN : 1.400 (-24.32%)
EMMLF : 0.0137 (-32.51%)
OKYO Pharma Limited Announces Pricing of Public Offering and Nasdaq Listing Globe Newswire - Mon May 16, 2022

LONDON, May 16, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a biotechnology company focused...

OKYO.LN : 1.400 (-24.32%)
EMMLF : 0.0137 (-32.51%)
OKYO Pharma ("OKYO" or the "Company") - Announces Two Presentations at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Globe Newswire - Wed Apr 27, 2022

OK-101 ameliorates neuropathic corneal pain in a mouse model of ciliary nerve ligation BAM8-22 peptide analog OK-201 alleviates neuropathic corneal pain...

OKYO.LN : 1.400 (-24.32%)
EMMLF : 0.0137 (-32.51%)
More news for this symbol

Barchart Technical Opinion

Strong sell

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 2.358
2nd Resistance Point 2.167
1st Resistance Point 1.783
Last Price 1.400
1st Support Level 1.208
2nd Support Level 1.017
3rd Support Level 0.633

See More

52-Week High 8.500
Fibonacci 61.8% 5.769
Fibonacci 50% 4.925
Fibonacci 38.2% 4.081
Last Price 1.400
52-Week Low 1.350

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot